Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

被引：1

作者：

Alanzi, Meshaal ^{[5
,6
]}

Abu-Tineh, Mohammad ^{[1
]}

Szabados, Lajos ^{[2
]}

Eldean, M. Z. Sharaf ^{[3
]}

Alatasi, Sali ^{[3
]}

Taha, Ruba Y. ^{[1
]}

Elkourashy, Sarah A. ^{[1
,4
]}

机构：

[1] Hamad Med Corp, Dept Internal Med, Doha, Qatar

[2] Natl Ctr Canc Care & Res, Dept Med Oncol Hematol, Doha, Qatar

[3] Natl Ctr Canc Care & Res, Hamad Med Corp, Dept Nucl Med, Doha, Qatar

[4] Hamad Med Corp, Dept Pathol, Doha, Qatar

[5] Weill Cornell Med Univ, Doha, Qatar

[6] Hamad Med Corp, Internal Med Resident, Al Rayan Rd, Doha, Qatar

来源：

ONCOTARGETS AND THERAPY | 2023年 / 16卷

关键词：

Burkitt?s lymphoma; polatuzumab; Lymphoma; anti CD79b; resistant lymphoma;

D O I：

10.2147/OTT.S394193

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first -line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt's lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.

引用

页码：133 / 139

页数：7

共 21 条

[1] Approved indication: B-cell lymphoma [J].

不详 .

AUSTRALIAN PRESCRIBER, 2020, 43 (06) :218-219

[2] Translocations involving c-myc and c-myc function [J].

Boxer, LM ;

Dang, CV .

ONCOGENE, 2001, 20 (40) :5595-5610

[3] Denis Burkitt and his contribution to haematology/oncology [J].

Coakley, Davis .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (01) :17-25

[4]

Crombie Jennifer, 2021, Blood, V137, P743, DOI 10.1182/blood.2019004099

[5] Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study [J].

da Silva, Wellington F. ;

Marques Garibaldi, Pedro Manoel ;

da Rosa, Lidiane Ines ;

Bellesso, Marcelo ;

Cle, Diego Villa ;

Delamain, Marcia Torresan ;

Rego, Eduardo Magalhaes ;

Pereira, Juliana ;

Rocha, Vanderson .

LEUKEMIA RESEARCH, 2020, 89

[6] Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial [J].

Diefenbach, Catherine ;

Kahl, Brad S. ;

Banerjee, Lalita ;

McMillan, Andrew K. ;

Miall, Fiona ;

Briones, Javier ;

Cordoba, Raul ;

Hirata, Jamie ;

Chang, YiMeng ;

Musick, Lisa ;

Abrisqueta, Pau .

BLOOD, 2019, 134

[7] Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma [J].

Dornan, David ;

Bennett, Fiona ;

Chen, Yvonne ;

Dennis, Mark ;

Eaton, Dan ;

Elkins, Kristi ;

French, Dorothy ;

Go, Mary Ann T. ;

Jack, Andrew ;

Junutula, Jagath R. ;

Koeppen, Hartmut ;

Lau, Jeffrey ;

McBride, Jacqueline ;

Rawstron, Andy ;

Shi, Xiaoyan ;

Yu, Nancy ;

Yu, Shang-Fan ;

Yue, Peng ;

Zheng, Bing ;

Ebens, Allen ;

Polson, Andrew G. .

BLOOD, 2009, 114 (13) :2721-2729

[8]

FDA, 2019, FDA APPR POL VED PII

[9] Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma [J].

Lap, Coen J. ;

Nassereddine, Samah ;

Dunleavy, Kieron .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (07)

[10] Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin [J].

Li, Dongwei ;

Lee, Donna ;

Dere, Randall C. ;

Zheng, Bing ;

Yu, Shang-Fan ;

Fuh, Franklin K. ;

Kozak, Katherine R. ;

Chung, Shan ;

Yadav, Daniela Bumbaca ;

Nazzal, Denise ;

Danilenko, Dimitry ;

Go, Mary Ann T. ;

Williams, Marna ;

Polson, Andrew G. ;

Poon, Kirsten Achilles ;

Prabhu, Saileta .

BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (19) :3805-3818

← 1 2 3 →